Patents Examined by Christina Bradley
  • Patent number: 10925923
    Abstract: The present invention provides a peptide having anti-inflammatory activity, composed of an amino acid sequence of a sequence listing of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. The peptide inhibits the expression of inflammatory cytokines and inhibits the proliferation of inflammatory cells, so as to resultantly exhibit anti-inflammatory activity, thereby being useful in the prevention or treatment of inflammatory diseases.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: February 23, 2021
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10913769
    Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 9, 2021
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
  • Patent number: 10905770
    Abstract: The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin).
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: February 2, 2021
    Assignee: MacRegen, Inc.
    Inventors: Keith Roizman, John Jacob Requard, III, Felicity Jane De Cogan
  • Patent number: 10898550
    Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: January 26, 2021
    Assignees: CASE WESTERN RESERVE UNIVERSITY, VERSITECH LIMITED
    Inventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng, Heng Li, Wutian Wu
  • Patent number: 10898583
    Abstract: Provided are compositions and methods for promoting tolerance to auto-immune antigens. In general the compositions include quantum dots (QDs) that are in association with auto-immune peptide antigens. It is shown that QDs can be used to generate immunological tolerance by controlling the density of self-antigen on QDs. Peptide-QDs rapidly concentrate in draining lymph nodes, and co-localize with macrophages expressing scavenger receptors involved intolerance. Treatment with peptide-QDs reduces disease incidence 10-fold. The degree of tolerance and the underlying expansion of regulatory T cells correlates with the density of myelin molecules presented on QDs such that higher numbers of tolerogenic particles displaying lower levels of self-peptide are more effective for inducing tolerance than fewer particles each displaying higher densities of peptide. The disclosure is therefore relevant to promoting tolerance to antigens that are involved in a variety of autoimmune disorders.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 26, 2021
    Assignees: University of Maryland, College Park, The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Christopher M. Jewell, Krystina Hess, Igor Medintz, Kimihiro Susumu, Eunkeu Oh
  • Patent number: 10898542
    Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: January 26, 2021
    Assignee: AFFILOGIC
    Inventor: Olivier Kitten
  • Patent number: 10889620
    Abstract: Solid state forms of Linaclotide, processes for their preparation, compositions comprising them and medical uses thereof are provided. The solid state forms of Linaclotide are useful in the preparation of other solid state forms of Linaclotide, particularly the amorphous form.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: January 12, 2021
    Assignee: NOVETIDE LTD.
    Inventors: Chaim Eidelman, Hagi Alon, Dov Vayer, Sharon Penias-Navon, Jonathan Enav
  • Patent number: 10882885
    Abstract: Described herein are novel synthetic molecules, polymers, and compositions comprising silica-binding peptides, and their methods of production. Also described herein are methods of synthesizing structurally and chemically complex silica-based materials using the synthetic molecules, polymers, and compositions.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: January 5, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Andrea Kimi Wallace, Maiko Furubayashi, Christopher A. Voigt
  • Patent number: 10870678
    Abstract: The present disclosure provides certain chiral peptide agents, and uses relating thereto.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 22, 2020
    Assignee: Arcuate Therapeutics, Inc.
    Inventor: Andrew D. Levin
  • Patent number: 10858393
    Abstract: According to the present invention, a crystal of reduced glutathione having a reduced content of impurities, particularly L-cysteinyl-L-glycine and a method for producing the same are provided. The present invention relates to a crystal of reduced glutathione, wherein, in a high-performance liquid chromatography (HPLC) analysis, the peak area of L-cysteinyl-L-glycine is 0.02 or less with respect to the peak area of reduced glutathione which is taken as 100.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 8, 2020
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Kazunari Fukumoto, Maya Iguchi, Hiroshi Nagano
  • Patent number: 10858655
    Abstract: The present invention provides compositions and methods for treating cancer with peptide nucleic acid agents. In some embodiments, the present invention provides methods and compositions relating to peptide nucleic acid agents that target oncogenes. For example, the present invention provides compositions, including pharmaceutical compositions, comprising agents specific for BRAF V600E inhibition, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using BRAF V600E specific peptide nucleic acid agents and/or compositions.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: December 8, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jeffrey H. Rothman, Gary K. Schwartz
  • Patent number: 10844105
    Abstract: De novo designed polypeptides that bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor ? subunit (IL-13R?) are disclosed, as are methods for using and designing the polypeptides.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 24, 2020
    Assignees: University of Washington, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daniel Adriano Silva Manzano, Shawn Yu, Umut Ulge, David Baker, Kenan Christopher Garcia, Jamie Spangler, Carl Walkey
  • Patent number: 10828296
    Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 10, 2020
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
  • Patent number: 10821065
    Abstract: The present invention relates to: a composition for inhibiting biofilms, containing, as an active ingredient, a peptide derived from human ?-defensin-3; and a method for inhibiting biofilms by using the composition. The peptide according to the present invention inhibits bacterial biofilms even when used alone and exhibits a remarkably increased biofilm inhibitory effect when used in combination with a conventional dental therapeutic agent, and has an effect of preventing a tooth discoloration side effect caused by a conventional dental therapeutic agent.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: November 3, 2020
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NIBEC CO., LTD.
    Inventors: Seung Hyun Han, Kee-Yeon Kum, Ki Bum Ahn, Ok-Jin Park, Chong-Pyoung Chung, Yoon Jeong Park, Jue-Yeon Lee
  • Patent number: 10813976
    Abstract: The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 27, 2020
    Assignee: NOVALIQ GMBH
    Inventors: Frank Löscher, Ralf Grillenberger, Johan Engblom
  • Patent number: 10815283
    Abstract: The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 27, 2020
    Assignee: Follicum AB
    Inventors: Jan Alenfall, Pontus Dunér, Anna Hultgårdh Nilsson, Björn Walse
  • Patent number: 10808039
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: October 20, 2020
    Assignee: Seattle Genetics Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
  • Patent number: 10808017
    Abstract: 53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 20, 2020
    Assignees: The Governing Council of the University of Toronto, Sinai Health System
    Inventors: Daniel Durocher, Sachdev Sidhu, Wei Zhang, Frank Sicheri, Marella Canny
  • Patent number: 10800822
    Abstract: Synthetic histatins composed of combinations of functional domains of natural histatins separated by exogenous linkers are described as are methods of using endogenous and synthetic histatins for the treatment of ocular diseases or conditions.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: October 13, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Vinay Aakalu
  • Patent number: 10793596
    Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: These compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 6, 2020
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo